 | Up a level |
Journal Article
Javle, Milind, Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa 
ORCID: 0000-0002-5856-4082, Weiss, Karl Heinz, Waldschmidt, Dirk-Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony, Borad, Mitesh J., Yong, Wei Peng, Philip, Philip A., Bitzer, Michael, Tanasanvimon, Surbpong, Li, Ai, Pande, Amit, Soifer, Harris S., Shepherd, Stacie Peacock, Moran, Susan, Zhu, Andrew X., Bekaii-Saab, Tanios S. and Abou-Alfa, Ghassan K.
(2021).
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Lancet Gastroenterol. Hepatol., 6 (10).
S. 803 - 816.
SAN DIEGO:
ELSEVIER INC.
ISSN 2468-1253
Makawita, Shalini, Kelley, Robin Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Yong, Wei-Peng, Borbath, Ivan, El-Khoueiry, Anthony B., Philip, Philip Agop, Moran, Susan, Ye, Yining, Soifer, Harris S., Li, Gary, Berman, Craig and Javle, Milind M. (2020). Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions. J. Clin. Oncol., 38 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755